Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index fell by 3.7%, while the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index decreased by 3.1% [1] - The total value of China’s innovative drug License-out transactions grew from $2.562 billion in 2017 to $140.274 billion by 2025, indicating enhanced international competitiveness [1] - Over 70% of innovative drug companies are expected to achieve positive revenue growth by 2025, marking a transition into a commercialization phase for the industry [1] Group 2 - The current valuation of the pharmaceutical sector is considered attractive, with a recommendation to focus on companies with clear overseas expansion opportunities and those with clinical data advantages in specific segments [1] - The ETF tracking the CSI Biotechnology Theme Index, managed by E Fund, has seen a decline of 0.3% [4] - The ETF tracking the CSI Pharmaceutical and Health Index, also managed by E Fund, has similarly decreased by 0.3% [4]

Group 1 - The Hong Kong stock market for innovative drugs is experiencing an upward trend, with the E Fund Hong Kong Stock Connect Innovative Drug ETF (159316) rising by 2.89% and the E Fund Hong Kong Stock Connect Medical ETF (513200) increasing by 2.33% [1] - The rebound in the sector is driven by three main factors: a surge in business development (BD) transactions, high growth performance forecasts, and improved liquidity [1] - Significant BD transactions in innovative drugs include a $18.5 billion collaboration between CSPC Pharmaceutical and AstraZeneca on January 30, and an $8.85 billion partnership between Innovent Biologics and Eli Lilly on February 8, marking record high upfront payments for Chinese pharmaceutical companies [1] Group 2 - The performance forecasts for innovative drug companies indicate a positive industry outlook, with Innovent Biologics, Rongchang Biologics, and Junshi Biosciences projecting revenues of approximately 11 billion, 3.25 billion, and 2.5 billion yuan for 2025, representing year-on-year growth of 45%, 89%, and 31.8% respectively [1] - Guotai Junan Securities anticipates a performance disclosure window for innovative drug companies in February and March, with several firms expected to reduce losses or turn profitable, and predicts that more companies will achieve profitability in 2026 [1] - Upcoming academic conferences such as AACR in April, ASCO in May, and ESMO in October are expected to further validate clinical data for domestic innovative drugs, indicating a clear upward trend in the industry [1] Group 3 - The E Fund Hong Kong Stock Connect Innovative Drug ETF (159316) is currently the only product tracking the Hang Seng Hong Kong Stock Connect Innovative Drug Index, focusing on core enterprises in the innovative drug industry and excluding CXO companies [2] - The E Fund Hong Kong Stock Connect Medical ETF (513200) tracks a broader medical index, covering key areas such as innovative drugs, medical devices, and medical services, with a total size of 1.695 billion yuan, making it the largest among similar ETFs [2] - The comprehensive fee rate for the E Fund Hong Kong Stock Connect Medical ETF is 0.2% per year, the lowest in its category, and it supports T+0 trading [2]

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index (HSSCID) has surged by 4.32%, while the E Fund Hong Kong Stock Connect Innovative Drug ETF (159316) has increased by 3.50%, marking a three-day consecutive rise [1] - Innovent Biologics has entered into a global strategic collaboration with Eli Lilly to advance the development of new drugs in oncology and immunology, with a deal size exceeding expectations [1] - Under the agreement, Innovent will lead the research and development of related projects from drug discovery to clinical proof of concept in China, while Eli Lilly will obtain exclusive development and commercialization rights outside Greater China [1] Group 2 - According to Zhongyou Securities, although the innovative drug sector has experienced short-term fluctuations due to funding issues, the global participation trend has been fully reflected in 2025 [2] - Domestic new drugs are transitioning from early research to a phase of efficiency, indicating that the innovative drug sector is expected to enter a harvest period in the medium term [2] - The E Fund Hong Kong Stock Connect Innovative Drug ETF closely tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Index, which aims to reflect the performance of Hong Kong-listed companies involved in innovative drug research, development, and production [2]

Core Viewpoint - The pharmaceutical sector experienced a collective pullback today, with various indices showing declines, while there is still significant capital inflow into innovative drug ETFs, indicating a potential recovery in demand for CRO and CDMO services [1]. Group 1: Market Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Index fell by 1.4% [1]. - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index and the CSI Innovative Drug Industry Index both decreased by 1.1% [1]. - The CSI Biotechnology Theme Index dropped by 0.8%, and the CSI 300 Pharmaceutical and Health Index declined by 0.7% [1]. - Despite the overall market decline, the E Fund Innovative Drug ETF (159316) saw a net subscription of over 20 million units throughout the day [1]. Group 2: Industry Outlook - According to Zhongtai Securities, multiple factors are driving a gradual recovery in demand for CRO and CDMO services within the pharmaceutical sector [1]. - The past three years have seen a continuous clearing of supply, suggesting that the sector may experience a "Davis Double Play" with simultaneous improvements in profitability and valuation [1].